E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 4.3 SEK -7.73% Market Closed
Market Cap: 1B SEK

Wall Street
Price Targets

ENZY Price Targets Summary
Enzymatica AB (publ)

Wall Street analysts forecast ENZY stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ENZY is 3.96 SEK with a low forecast of 2.71 SEK and a high forecast of 5.34 SEK.

Lowest
Price Target
2.71 SEK
37% Downside
Average
Price Target
3.96 SEK
8% Downside
Highest
Price Target
5.34 SEK
24% Upside
Enzymatica AB (publ) Competitors:
Price Targets
APPH
Apontis Pharma AG
28% Upside
000739
Apeloa Pharmaceutical Co Ltd
28% Upside
ZYDUSLIFE
Zydus Lifesciences Ltd
22% Upside
EYPT
EyePoint Pharmaceuticals Inc
470% Upside
ORCHPHARMA
Orchid Pharma Ltd
97% Upside
2005
SSY Group Ltd
69% Upside
600566
Hubei Jumpcan Pharmaceutical Co Ltd
91% Upside
AJANTPHARM
Ajanta Pharma Ltd
13% Upside

Revenue
Forecast

Revenue Estimate
Enzymatica AB (publ)

For the last 8 years the compound annual growth rate for Enzymatica AB (publ)'s revenue is 3%. The projected CAGR for the next 2 years is 56%.

3%
Past Growth
56%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Enzymatica AB (publ)

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat

Net Income
Forecast

Net Income Estimate
Enzymatica AB (publ)

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ENZY's stock price target?
Price Target
3.96 SEK

According to Wall Street analysts, the average 1-year price target for ENZY is 3.96 SEK with a low forecast of 2.71 SEK and a high forecast of 5.34 SEK.

What is Enzymatica AB (publ)'s Revenue forecast?
Projected CAGR
56%

For the last 8 years the compound annual growth rate for Enzymatica AB (publ)'s revenue is 3%. The projected CAGR for the next 2 years is 56%.

Back to Top